



NIH PUBLIC ACCESS

Author Manuscript

Nat Rev Genet. Author manuscript; available in PMC 2011 March 1.

Published in final edited form as:

Nat Rev Genet. 2010 September ; 11(9): 658–662. doi:10.1038/nrg2864.

The Ethics of Using Transgenic Non-Human Primates to Study What Makes Us Human

Marilyn E. Coors¹, Jacqueline J. Glover¹, Eric T. Juengst², and James M. Sikela³¹Center for Bioethics and Humanities, School of Medicine, University of Colorado Denver²Department of Pharmacology, School of Medicine, University of Colorado Denver³Center for Bioethics, School of Medicine, University of North Carolina, Chapel Hill

Abstract

An ongoing flood of comparative genomic data is identifying human lineage specific (HLS) sequences of unknown function, and there is strong interest in investigating their functional effects. Transgenic apes, our closest evolutionary relative, have the highest potential to express HLS sequences as they are expressed in *Homo sapiens* and likewise experience harm from such transgenic research. These harms render the conduct of this research ethically unacceptable in apes, justifying regulatory barriers between these species and all other non-human primates for transgenic research.

INTRODUCTION

The publication of the draft sequence of the common chimpanzee genome in September 2005 was heralded as an advance that confirmed what Darwin¹ and Huxley² posited more than a century ago: humans share common ancestors with African great apes^{3,4}. In addition to highlighting vast homologies between human and chimpanzee DNA, primate comparative genomics is also providing insights into the question of what makes members of *Homo sapiens* different from their nearest evolutionary relatives.. There is great interest in identifying the genetic factors that underlie the traits that are traditionally taken to be the hallmarks of our species: higher cognition⁵, complex language and vocalizations systems⁶, skin phenotypes⁷, immune and reproduction system function^{8,9}, sensory perception^{10,11}, degree of self and social awareness¹², and other idiosyncrasies of our physiology, anatomy and behavior¹³. While computational predictions of function can be made from large datasets, determining which sequences are functionally related to complex lineage-specific phenotypes can likely be accomplished by experimental investigation.

One potentially appealing experimental strategy is to investigate functional effects of HLS sequences in transgenic non-human primates (NHPs). Ideally, the species chosen for this research should be those who share the greatest genetic similarity with *Homo sapiens*, to increase the likelihood that they will express the HLS sequences in ways that give a clear indication of their function in humans. While the long generation times of apes makes them less than ideal for genetic studies, their highly similar genetic background with humans makes them a particularly attractive host species for transgenic studies of the function of HLS sequences. However, we argue that the scientific insights that can potentially be gained by this approach are outweighed by ethical concerns regarding the generation of such “humanized” apes. The same evolutionary proximity that makes this research strategy attractive renders it ethically unacceptable in apes, including greater apes (chimpanzees, orangutans, bonobos, gorillas) and lesser apes (gibbons), because apes have the greatest potential to produce human-like phenotypes and, as such, carry a unique potential for harm.

HUMAN LINEAGE-SPECIFIC SEQUENCES

In addition to the human genome sequence¹⁴, we now have the complete draft genome sequences of chimpanzee⁴ and rhesus macaque¹⁵. Draft assemblies are currently available for the gorilla, orangutan, marmoset, and lemur (<http://www.ensembl.org/index.html>), and a draft Neanderthal genome sequence has recently been published¹⁶. In addition, draft sequences of bonobo and baboon are underway (<http://www.genome.gov/10002154>). These data-sets are providing a rich and unprecedented resource for mining lineage-specific genomic changes among humans and NHPs. Evolutionary genomics has already uncovered a wide range of HLS sequences. Genes affected include those that show striking HLS increases or decreases in copy number^{17,18,19}, genes that have changed dramatically at the sequence level specifically in humans²⁰, and genes that show altered brain expression between human and chimpanzee^{21,22}.

These genes span a range of functional characteristics, from those with no known function to those implicated in various anatomical and physiological processes⁵, including several linked to higher cognitive functions^{20,22,23}. We can expect that, as more and more primate genomes are completed, the list of HLS genomic changes will significantly expand and further stimulate interest in understanding the functional consequences of such changes. This in turn can be expected to generate an increased interest in using transgenic animals as a means of studying HLS gene function.

TRANSGENIC RESEARCH USING NHPs

For uniquely human sequences or genes, transgenic research using NHPs could likely be accomplished with existing techniques, either through homologous exchange of HLS sequence with homologous sequence of the transgenic host species or addition of HLS sequences to the host genome^{24,25,26,27}. However, new advances will be required to study functional consequences of differences in expression, since precisely altering expression levels in transgenic research by increasing copy number or modifying the regulatory region of a gene remains technically challenging. Nevertheless, improving our abilities to control the number and genomic location of copies of integrated transgenes and levels of temporal and spatial expression is a high priority goal within human gene transfer research, due to the critical implications for the safety and efficacy of human gene therapy and other treatments.

A common application of transgenic animal technology has been the generation of mouse models to study a number of human disorders, including neurodegenerative disorders²⁸, autoimmune diseases^{29,30}, and cancer³¹. Nevertheless, even though there are National Institutes of Health-supported efforts aimed at “humanizing” mice by development of transgenic strains that contain human-specific alleles (RFA-MH-08-050) and a recent study has examined the function of human alleles of the FOXP2 gene in transgenic mice³², there are limits to what scientists can learn about the function of human genetic sequences in mice because of the significantly different genetic backgrounds of the two species. There are also considerable anatomical and physiological differences between these species that may interfere with such an approach. In particular, there are large differences in relative size and composition between rodents and humans in areas of the brain associated with higher cognition. Thus, the possibility of anything near human cognition resulting from HLS sequences transferred to a mouse using conventional transgenic approaches is remote.

Recently there has been a shift towards using NHP models³³. The creation of chimeras through the interspecies transfer of stem cells is one means of exploring the function of the HLS sequences. The ethical concerns raised by the interspecies transplantation of human brain, retinal stem cells, and other cells to nonhuman embryos or fetuses are addressed in the literature^{34,35,36,37}. The production of chimeras entails the transfer of an entire genome to

the host species, while the creation of transgenics, which is the focus of this article, indicates the transfer a genomic sequences(s) to the host. The first transgenic NHP was produced in 2001, and in 2008 a rhesus macaque that expressed hallmark features of Huntington's Disease became the first transgenic monkey model of human disease, raising the hope of ultimately developing new therapies³⁸. Another experimental approach is the recently reported generation of transgenic NHPs to study mitochondrial gene replacement in primate offspring²⁶. The goal of developing new therapeutic approaches using these methods is an admirable one, yet it raises important ethical questions and points to the need to distinguish between the use of apes and all other NHPs ("monkeys" hereafter).

The basic rationale for pursuing transgenic research on HLS sequences is that it could provide important information regarding the basic scientific question of what makes members of *Homo sapiens* different from their nearest evolutionary cousins. The research continuum from bench to bedside suggests that results of transgenic research may also produce clinical benefits, especially given that HLS gene variants have been found to be disproportionately enriched in genomic locations implicated in human diseases^{19,21}. Another key factor is evidence that evolutionary mechanisms that have produced rapid genomic changes in the human lineage often produce human disease as a byproduct²⁵. It is possible that HLS variants that affect human phenotype could provide important insights into disorders and clinically relevant phenotypes that are difficult to study by other means, including cognitive disease²⁵, neurodegenerative disorders³⁸, social behavior disorders such as autism³⁹, dementia⁴⁰, speech articulation defects^{41,21}, and gene delivery systems⁴² for therapeutic use. Since this research is still in the early stages and the benefits still theoretical, it is appropriate to examine proactively the ethical concerns related to NHP transgenic research.

ANIMAL WELFARE REGULATIONS

The prospect of conducting transgenic NHP research differs according to country; no international animal welfare regulations exist at present but the OIE World Assembly of National Delegates adopted a 5th Strategic Plan for pursuing OIE global mission in animal health and welfare in 2010 (http://www.oie.int/eng/session2010/press_p_releases.htm). Currently, transgenic research involving all NHPs could be approved in countries, including the United States and China, that have no specific bans^{43,44,45,46,47}. The use of great apes for most research is effectively banned in the United Kingdom, New Zealand, the Netherlands, Austria, and Sweden^{48,49,50}. The ban in Austria and Sweden also includes the lesser apes⁵¹. And the European Union is now considering updates to their animal welfare laws that would mirror requirements in the United Kingdom^{52,53}. Although monkeys are used for research in the United Kingdom, regulations require additional oversight, including a special license for the individual researcher, project, and institution^{47,54}.

Animal welfare regulations and guidelines vary around the world, but all share a commitment to what is known as the Three Rs: replacement, reduction, and refinement. The Three Rs state that animals should only be used if there is no alternative and, when animals are necessary, only the most humane methods should be used on the smallest number of animals required for scientific validity^{43,45,49,55,56,57}. However, the Three Rs are criticized by some for not providing a way to give special consideration to certain species, such as NHPs⁴⁶.

THE ETHICAL ISSUES

Predictive and Diagnostic Uncertainty in Transgenic NHP Research

The transfer of an HLS gene or genomic variant into an NHP could have a specific, discreet effect that has a more or less dramatic impact on a phenotype of relevance to human function. However, biomolecular systems are interdependent, and most genes appear to have multiple functions that can be seemingly unrelated. So, such a transfer could just as easily have a wide array of unexpected and/or deleterious effects. For example, even if gene targeting could be carried out specifically, the pleiotropic nature of most genes will often make the phenotypic impact of a transgenic intervention extremely difficult to predict or interpret and may not emerge immediately but only as offspring are produced, even if studied first in other animals^{21,58}. This uncertainty raises the risk of producing unanticipated harm to transgenic NHPs. Moreover, if HLS gene transfer actually accomplishes its intended aim and produces a measurable change in a "human-like" NHP phenotype, this would raise another set of ethical concerns. Even if a transgenic NHP remotely displayed phenotypic traits that made it only slightly more similar to a human...there would be further ethical questions concerning the animal's vulnerability to harm.

Ethical Obligations towards NHPs in Transgenic Research

The debate about animal welfare in general, and the use of primates in particular, is often carried out in the literature in terms of "moral status", a term meant to describe what entities are owed in their own right rather than as instrumental value to others^{59,60}. Moral status is not an all or nothing assessment since ethically justified regulations allow research on humans and prohibit capricious animal use. Additionally, consideration of our ethical obligations to humans and animals is not dependent on inherent capacities alone, but also includes relational elements. For example, this consideration is applied to humans who lack many human capacities and to companion animals like cats, dogs, and horses that lack higher order capacities. Merely labelling an entity as having or lacking moral status cannot do the ethical work of sorting out our particular obligations. Rather, ethical obligations are to be determined by carefully assessing the answers to at least five questions: What are the goals of research? What is the probability of success? Which animals are to be used? What effect will there be on the animals used? Are there any alternatives? These questions represent a moderate approach to the ethics of animal research: they assume that some animal research is warranted and can be ethically justified, but also recognize that not every scientific finding automatically outweighs the interests and welfare of the animals that its demonstration might require⁶¹.

There is a growing literature on ethical issues in the creation and research use of transgenic and chimeric animals in general, and primates in particular. Some analysts try to articulate the unique concerns in transgenic research in terms of the "unnaturalness" of "crossing species boundaries," citing unspecified downstream evolutionary and ecological risks^{62,63}. Others turn to notions of "animal integrity" or "species-specific dignity" to try to focus their critiques on the impact of transgenic manipulations on the animals themselves^{35,64,65,66}. This approach is headed in the right direction, but it usually remains at a relatively abstract level that is hard to apply to the actual conduct of animal research. It can be both strengthened and sharpened by considering the purely biological challenges that any transgenic apes that actually express humanized phenotypes would face. At the far end of the spectrum, of course, are cognitive changes that might give transgenic apes enough self-awareness to appreciate the ways their lives are circumscribed and to suffer, albeit immeasurably, in the full psychological sense of that term. But it is not necessary to go that far. Imagine the life of the transgenic chimpanzee that, while no more self-aware than other chimps, is hairless, walks erect, lacks long canine teeth, or vocalizes like a human. There

may be no question of a "normal" primate life in the wild for this chimp: it is likely to be condemned by its engineering to live in a human environment. Outside the laboratory, this chimp could well be considered a grotesque curiosity and unusually susceptible to exploitation and inappropriate treatment for commercial gain. Within the laboratory colony, moreover, the transgenic chimp is unlikely to be able to be socially successful with its own species either and potentially viewed as strange and an outcast by those without its differences. Ill-suited for both worlds, the humanized chimp is likely to sustain more injuries and encounter more privations than the unengineered inhabitants of either species.

Apes share many capacities with humans such as the capacity for attachment and empathy, communication, internalization of social rules, giving, trading, revenge, social maintenance, and attending to group boundaries. Such capacities could exacerbate the harms to these animals. If "humanizing" expressions of HLS sequences only served to inhibit or destroy the characteristics that these apes already share with us, we have harmed them, even from a human "speciesist" point of view. Since it is hard to imagine a case of transgenic HLS sequence research in apes in which these social harms and the physical welfare concerns they generate would not arise, it is reasonable to conclude that this research will almost never be ethically acceptable. For policy purposes, this conclusion supports higher regulatory barriers, in terms of safeguards and review, against any transgenic HLS sequence research with apes.

Of course, monkeys also display many of these same social and behavioral characteristics. To that extent, should they enjoy the protections as apes when it comes to transgenic research with HLS sequences? Clearly there is an evolutionary spectrum between the great apes, monkeys, and lemurs, and any line-drawing that occurs across it will be to some extent arbitrary. The evolutionary and genomic distance between monkeys and humans is great enough to diminish the prospect that a simple HLS sequence insertion in a monkey genome will produce human-like phenotypes, or that those phenotypes will be as socially challenging for monkeys as they would be for apes. Because of the greater evolutionary distance between humans and monkeys compared to humans and apes, more genetic changes would be needed in monkeys to elicit a human-like phenotype than would be needed if apes were used as the host species. Consequently, there is a greater chance that using apes as HLS hosts would produce a transgenic with a human-like phenotype than if a monkey were the host species. Accordingly, because apes would more easily be humanized, and the traits would likely be more human-like than if a monkey host were the host species. For this reason, such humanized apes would be at greater risk for exploitation. From the ethical point of view, the more social and cognitive capacities primates possess, the weightier our obligations to them become. However, if a line is needed for policy and regulatory purposes, the line between the ape and monkeys is relatively clean. This reduced risk of harm of a human-like phenotype, suggests that transgenic HLS sequence research with monkeys may not always be ethically objectionable and could be regulated on a case-by-case basis by institutional animal care and use committees, including public representation in the form of a community member.

CONCLUSIONS

A few conclusions can be drawn from this discussion. First, because of the close evolutionary genomic proximity, transgenic apes have the greatest potential to express HLS sequences as they are expressed in *Homo sapiens* and consequently experience harm from transgenic research. This is in part due to the fact that humanized transgenic apes would likely exhibit traits that are the most human-like, putting them at greater risk of exploitation. Second, the challenge of assessing our ethical obligations to "humanized" apes is profound. The ethical concerns raised by the generation and use of apes as transgenic hosts to study

HLS sequence function render this research ethically unacceptable, justifying regulatory barriers between these species and monkeys. Concurrently, we recommend that the possible use of monkeys in transgenic HLS research be examined on a case-by-case basis by animal welfare review boards, with special attention paid to the unique issues in careful application of the Three Rs in primate research. Some information regarding HLS gene function can be potentially be obtained using HLS transgenic mice. Of course, another alternative would be to use clues given to us by comparative identification of HLS sequences in further studies of members of our own species. While the NHP genome is similar to ours, there are also significant differences. Thus, there are limits to what we can learn about the function of HLS variants until we study them in the human genome where they may exist as naturally-occurring variations. By this more direct means we can potentially identify deficiencies or mutations in HLS sequences, and phenotypes that seem to accompany these changes. Human HLS research is also laden with serious ethical questions about what it might mean for a human to lack the hallmarks of “humanness”, and how that research might be used and potential harms and abuses avoided. Those ethical questions deserve their own further analysis.

Acknowledgments

The authors wish to acknowledge the assistance of Christopher J. McCormick, Majesta O’Bleness, Laura Dumas, Jonathan Dang and Mark Douse, PhD for critical reading and preparation of the manuscript.

James M. Sikela is supported by NIH grants R01-MH081203 and RO1-AA11853. Marilyn E. Coors is supported by 5P60DA011015 and RO1-DA029258. Eric T. Juengst is supported by P50-HG03390.

References

1. Darwin, C. *The Descent of Man, and Selection in Relation to Sex*. New York: D Appleton and Company; 1871.
2. Huxley, TH. *Evidence as to Man’s Place in Nature*. London: Williams and Norgate; 1863.
3. Lovejoy CO, Suwa G, Simpson SW, Matternes JH, White TD. The great divides: *Ardipithecus ramidus* reveals the postcrania of our last common ancestors with African apes. *Science* 2009;326:100–106. [PubMed: 19810199]
4. Chimpanzee Sequencing and Analysis Consortium, Initial Sequence of the Chimpanzee Genome and Comparison with the Human Genome. *Nature* 2007;437:69–87.
5. Sikela JM. The Jewels of Our Genome: The Search for the Genomic Changes Underlying the Evolutionarily Unique Capacities of the Human Brain. *PLoS Genet* 2006;2:e80. [PubMed: 16733552]
6. Konopka G, et al. Human-specific transcriptional regulation of CNS development genes by FOXP2. *Nature* 2009;12:169–170.
7. Hedlund M, et al. N-glycolylneuraminic acid deficiency in mice: implications for human biology and evolution. *Mol. Cell Biol* 2007;27:4340–4346. [PubMed: 17420276]
8. Varki A, Altheide TK. Comparing the human and chimpanzee genomes: searching for needles in a haystack. *Genome Res* 2005;15:1746–1758. [PubMed: 16339373]
9. McConkey EH, Varki A. Thoughts on the future of great ape research. *Science* 2005;309:1499–1501. [PubMed: 16141054]
10. Go Y, Niimura Y. Similar numbers but different repertoires of olfactory receptor genes in humans and chimpanzees. *Mol. Biol. Evol* 2008;25:1897–1907. [PubMed: 18562338]
11. Wang X, Thomas SD, Zhang J. Relaxation of selective constraint and loss of function in the evolution of human bitter taste receptor genes. *Hum. Mol. Genet* 2004;13:2671–2678. [PubMed: 15367488]
12. Herrmann E, Call J, Hernandez-Lloreda MV, Hare B, Tomasello M. Humans have evolved specialized skills of social cognition: the cultural intelligence hypothesis. *Science* 2007;362:731–744.

13. Taylor, J. Not a Chimp, The hunt to find the genes that make us human. New York: Oxford University Press; 2009.
14. Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. *Nature* 2004;431:931–945. [PubMed: 15496913]
15. Rhesus Macaque Genome Sequencing and Analysis Consortium. Evolutionary and biomedical insights from the Rhesus macaque genome. *Science* 2007;316:222–234. [PubMed: 17431167]
16. Greene RE, et al. A draft sequence of the Neandertal Genome. *Science* 2010;328:710–722. [PubMed: 20448178]
17. Fortna A, et al. Lineage-specific gene duplication and loss in human and great ape evolution. *PLoS Biol* 2004;2:937–954.
18. Popesco MC, et al. Human Lineage-Specific Amplification, Selection, and Neuronal Expression of DUF1220 Domains. *Science* 2006;313:1304–1307. [PubMed: 16946073]
19. Dumas L, et al. Gene copy number variation spanning 60 million years of human and primate evolution. *Genome Res* 2007;17:1266–1277. [PubMed: 17666543]
20. Pollard KS, et al. Forces shaping the fastest evolving regions in the human genome. *PLoS Genet* 2006;13e:168.
21. Enard W, et al. Molecular evolution of FOXP2, a gene involved in speech and language. *Nature* 2002;418:869–872. [PubMed: 12192408]
22. Caceres M, et al. Elevated gene expression levels distinguish human from non-human primate brains. *Proc. Natl. Acad. Sci. USA* 2003;100:13030–13035. [PubMed: 14557539]
23. Dumas L, Sikela JM. DUF1220 domains, cognitive disease, and human brain evolution. *Cold spring Harb. Symp. Quant. Biol.* 2009 October 22; [Epub ahead of print].
24. Tachibana M, et al. Mitochondrial gene replacement in primate offspring and embryonic stem cells. *Nature* 2009;461:367–372. [PubMed: 19710649]
25. Kuang H, Wang P, Rsiem JZ. Towards transgenic primates: what can we learn from mouse genetics? *Sci. Chi. C. Life Sci* 2009;52:506–514.
26. Chan AWS, Chong KY, Martinovich C, Simerly C, Schatten G. Transgenic monkeys produced by retroviral gene transfer into mature oocytes. *Science* 2001;291:309–312. [PubMed: 11209082]
27. Yang SH, et al. Towards a transgenic model of Huntington’s disease in a non-human primate. *Nature* 2008;453:863–864.
28. Kurt S, Groszer M, Fisher SE, Ehret G. Modified sound-evoked brainstem potentials in Foxp2 mutant mice. *Brain Res* 2009;1289:30–36. [PubMed: 19596273]
29. Koyanagi Y, Tanaka Y, Ito M, Yamamoto N. Humanized mice for human retrovirus infection. *Curr. Top. Microbiol. Immunol* 2008;324:133–148. [PubMed: 18481458]
30. Mangalam A, Rajagopalan G, Taneja V, David CS. HLA class II transgenic mice mimic human inflammatory diseases. *Adv. Immunol* 2008;97:65–147. [PubMed: 18501769]
31. Blanco-Aparicio C, et al. Exploring the gain of function contribution of AKT to mammary tumorigenesis in mouse models. *PLoS One* 2010;5e:9305.
32. Enard W, et al. A humanized version of Foxp2 affects cortico-basal ganglia circuits in mice. *Cell* 2009;137:800–802. [PubMed: 19490887]
33. Chan AWS, Yang SH. Generation of transgenic monkeys with human inherited genetic disease. *Methods*. 2009 [Epub].
34. Skene L, Testa G, Hyun I, Jung KW, McNab A, Robertson J, Scott CT, Solbakk JH, Taylor P, et al. Ethics report on interspecies somatic cell nuclear transfer research. *Cell Stem Cell* 2009;5(1): 27–30. [PubMed: 19570511]
35. Degrazia D. Human-animal chimeras: human dignity, moral status, and species prejudice. *Metaphilosophy* 2007;38:309–329.
36. Greene M, Schill K, Takahashi S, Bateman-House A, Beauchamp T, Bok H, et al. Moral issues of human-non-human primate neural grafting. *Science* 2005;309:385–386. [PubMed: 16020716]
37. Karpowicz P, Cohen CB, van der Kooy D. Developing human-non-human chimeras in human stem cell research: ethical issues and boundaries. *Kennedy Instit Ethics J* 2005;15:107–129.
38. Chan AWS. Transgenic nonhuman primates for neurodegenerative disorders. *Reproduct. Biol. Endocrinol* 2004;2:39.

39. Geschwind DH, Levitt P. Autism spectrum disorders: developmental disconnection syndromes. *Curr. Opin. Neurobiol* 2007;17:103–111.
40. Seeley WW, et al. Early frontotemporal dementia targets neurons unique to apes and humans. *Ann. Neurol* 2006;60:660–667. [PubMed: 17187353]
41. Fisher SE, Scharff C. FOXP2 as a molecular window into speech and language. *Trends Genet* 2009;25:166–177. [PubMed: 19304338]
42. Romano G, Marino IR, Pentimalli F, Andamo V, Giordano A. Insertional mutagenesis and development of malignancies induced by integrate gene delivery systems: implications for the design of safer gen-based interventions in patients. *Drug News Perspect* 2009;22:185–196. [PubMed: 19536363]
43. Animal Welfare Act. 7 U.S.C. 2131 et seq. This can be found at the U.S. Government Printing Website. 2003. <http://www.access.gpo.gov/usecose/uscmain.html>
44. National Research Council National. Guide for the Care and Use of Laboratory Animals Prepublication Draft. Washington DC: National Academy Press; 2010. http://www.nap.edu/catalog.php?record_id=12910
45. United States Code of Federal Regulations. Animal Welfare Regulations: Title 9, Chapter 1, Subchapter A, Parts 2.31 and 2.32. Government Printing Office. 2007
46. Institute of Laboratory Animal Resources Commission on Life Sciences of the National Research Council. Guide for the Care and Use of Laboratory Animals. Washington D.C.: National Academy Press; 1996.
47. Kong Q, Qin C. Analysis of Current Laboratory Animal Science Policies and Administration in China. *ILAR e-Journal* 2010;51e:1–10.
48. Fenwick N, Griffin G, Gauthier C. The welfare of animals used in science: How the “Three Rs” ethics guides improvements. *CVJ* 2009;50:523–530.
49. Weatherall, D. The Use of non-human primates in research: A working group report chaired by Sir David Weatherall. 2006. <http://www.acmedsci.ac.uk>
50. United Kingdom Animals (Scientific Procedures) Act of 1986. 5(5)a and 5(4). 1986. www.opsi.gov.uk/acts/acts1986/pdf/ukpga_19860014_en.pdf
51. Luy J. Ethical and legal aspects of animal experiments on non-human primates. *Dtsch. Tierarztl. Wochenschr* 2007;114:81–85. [PubMed: 17419539]
52. European Commission, Laboratory Animals, Directive 86/609/EEC, adopted proposal to revise 2008. http://ec.europa.eu/environment/chemicals/lab_animals/nextsteps_en.htm
53. http://ec.europa.eu/environment/chemicals/lab_animals/nextsteps_en.htm
54. Griffin G. Establishing a three Rs programme at the Canadian council on animal care. *Altern. Lab Anim* 2009;37 Suppl 2:63–67. [PubMed: 20105015]
55. Takahashi-Omoe H, Omoe K. Animal experimentation in Japan: regulatory processes and application for microbiological studies. *Compar. Immunol. Microbio. Infect. Dis* 2007;30:225–246.
56. Omoe H. Recent trends in animal experimentation in Japan – on the revision and implementation of the law for humane treatment and management of animals. *Sci. Tech. Trends Quart. Rev* 2006;21:13–31.
57. London, England: 2004. National Center for Replacement, Refinement, and Reduction of Animals in Research. <http://www.nc3rs.org.uk/>
58. Coors M, Hunter L. Evaluation of genetic enhancement: will human wisdom properly acknowledge the value of evolution? *Am. J. Bioethics* 2005;5:21–22.
59. Warren, MA. Moral status: obligations to persons and other living things. New York: Oxford University Press; 1997.
60. Nuffield Council on Bioethics. The ethics of research involving animals. 2005. <http://www.nuffieldbioethics.org/go/ourwork/animalresearch/introduction>
61. Banner, M. Ethics, Society and Policy: A Way Forward. In: Holland, A.; Johnson, A., editors. *Animal Biotechnology and Ethics*. London: Chapman & Hall; 1998. p. 325-339.
62. Robert JS, Baylis F. Crossing Species Boundaries. *Am J Bioeth* 2003;3(3):1–13. [PubMed: 14594461]

63. Juengst, ET. Annotating the moral map of enhancement: gene doping, the limits of medicine and the spirit of sport, ". In: Murray, Tom, editor. *Ethics, Genetics and the Future of Sport: Implications of Genetic Modification and Genetic Selection*. Washington DC: Georgetown University Press; 2009.
64. Brent L. Life-long well being: applying animal welfare science to nonhuman primates in sanctuaries. *J. appl. Anim. Welf. Sci* 2007;10:55–61. [PubMed: 17484679]
65. Sughrue ME, et al. Bioethical considerations in translational research: primate stroke. *Am. J. Bioeth. Neurosci* 2009;9:3–12.
66. de Waal FB. A century of getting to know the chimpanzee. *Nature* 2005;437:56–59. [PubMed: 16136128]